Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

NEW YORK – The first patient with an advanced, MTAP-deleted solid tumor has received Tango Therapeutics' PRMT5 inhibitor TNG456 in a Phase I/II trial, the company said Wednesday. The Boston-based firm ...

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

NEW YORK – Fractyl Health has submitted the first module of a clinical trial application with European regulators seeking to begin a first-in-human study of its investigational gene therapy for type 2 ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.